FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| * * uoi iii i | gion, E | 20 | 0.10 | |
|---------------|---------|----|------|--|
| | | | | |
| | | | | |

| OMB APPROVAL | | | | | | | | | |
|--------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| OWD ALL IN | JVAL | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

| | | | | | or S | Section | n 30(h | n) of the | Investme | nt Co | ompany Act | of 1940 | | | | | | |
|--|---|--|--|---------------|--|--|-----------------|-----------|---|---|---|--|---|---|---|--|--|------------|
| 1. Name and Address of Reporting Person* Fenimore Christopher R. | | | | | RE | 2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS, INC. [REGN] | | | | | | | | | Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify) | | | |
| (Last) (First) (Middle) | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 01/23/2024 X Officer (give title Other (specify below) SVP Controller | | | | | | | | | | poony | | |
| 777 OLD SAW MILL RIVER ROAD | | | | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | | | | | plicable | | |
| (Street) TARRYTOWN NY 10591 | | | | _ | Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | | | | | - 1 | | |
| (City) (State) (Zip) | | | | | | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | |
| | | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | |
| Date | | | 2. Transa Date (Month/E | | Execution Date, | | Transaction Dis | | Disposed | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and | | and 5) Securities Beneficially Owned Following | | Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | | | (Instr. 4) |
| Common | Stock | | | 01/23 | 1/23/2024 | | | | М | | 5,000 |) A | \$555.0 | 57 21 | 7 21,860 | | D | |
| Common | Stock | | | 01/23/2024 | | \perp | | | F | | 3,986 | D | \$948. | 5 17 | 7,874 | | D | |
| Common | Stock | | | 01/23 | /2024 | \perp | | | M | | 5,000 | A | \$399. | 6 22,874 | | 4 D | | |
| Common | Stock | | | 01/23 | /2024 | 2024 | | | | | 3,583 | D \$94 | | 5 19 | 19,291 | | D | |
| Common Stock | | | | | | | | | | | | | 1, | ,473 | | | 2021 GRAT | |
| Common Stock | | | | | | | | | | | | | 4, | 269 | | | 2022 GRAT | |
| Common Stock | | | | | | | | | | | | | 1, | 1,499 | | Ι . | By 401(k) Plan | |
| Common Stock | | | | | | | | | | | | | 1, | 897 | | | By Trust ⁽¹⁾ | |
| Common Stock | | | | | | | | | | | | 461 | | I I | | by Trust for Daugh | | |
| Common Stock | | | | | | | | | | | | 4 | 460 | | | by Trust for Son | | |
| | | T | able II - | | | | | | | | osed of | | | Owned | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deem Execution if any (Month/Da | ed n Date, | 4. Transac Code (I 8) | action of E | | 6. Date E | S. Date Exercisable and Expiration Date Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | erivative derivative scurity Securities | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercisa | | Expiration Date | Title | Amount or Number of Shares | | | | | |
| Non- Qualified Stock Option (right to buy) | \$399.66 | 01/23/2024 | | | M | | | 5,000 | (2) | | 12/16/2024 | Common Stock | 5,000 | \$0.0 | 0 | | D | |
| Non- Qualified Stock Option (right to buy) | \$555.67 | 01/23/2024 | | | М | | | 5,000 | (2) | | 12/16/2025 | Common Stock | 5,000 | \$0.0 | 0 | | D | |
| | n of Bosnon | · · · · · · · · · · · · · · · · · · · | | | | | | | | | | | | | | | | |

2. The stock option award vests in four equal annual installments, commencing one year after the date of grant.

/s/**Christopher R. Fenimore 01/24/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.